Skip to main content

Table 1 Patients' dosimetric data

From: Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy

Patient

Type

Site number

Hb (g/dL)

BL time (weeks)

FU time (weeks)

MR

D(Gy)

Volume BL (ml)

1

mel.

1

10.0

−0.2

6.1

0.74

233.2   52.1

11

2

   

1.14

130.0   42.3

31

2

CRC

1

13.4

−6.2

8.1

0.11

169.9   79.9

58

2

   

4.00

6.1   8.2

17

3

CRC

1

11.1

−3.2

7.2

0.18

172.2   55.8

127

4

CRC

1

14.8

−2.3

6.2

0.15

110.9   33.1

93

2

   

6. 25

52.1   18.5

34

3

   

19.52

5.0   10.8

11

4

   

20.20

6.4   12.4

25

5

   

1.67

18.5   17.0

32

6

   

1.43

8.4   11.6

37

7

   

3.33

7.9   7.6

6

8

   

0.10

131.0   29.8

10

5

CRC

1

14.3

−3.5

7.2

0.05

178.5   35.2

34

2

   

1.75

20.4   6.1

6

6

CRC

1

13.0

−2.9

6.1

0.32

113.9   21.9

3

2

   

0.34

114.7   14.8

3

3

   

0.22

127.3   24.8

4

4

   

49.32

14.6   2.8

5

5

   

0.86

52.0   9.6

3

6

   

0.89

55.5   10.7

4

7

CRC

1

13.1

−0.6

6.1

1.32

52.2   10.6

37

2

   

2.08

26.6   6.2

36

8

mel.

1

13.4

−0.2

7.0

0.26

115.0   17.8

7

  

2

   

0.17

147.0   21.2

6

  1. BL, baseline FDG; CRC, colorectal cancer; D, dose; FU, follow-up FDG; Hb, hemoglobin; mel., melanoma; MR, tumor metabolic ratio.